

New Series, Volume 57, Issue 3, September 2022, ISSN 1584-9244 (print), 2558-815X (online)

ARCHIVES

OF THE

BALKAN  
MEDICAL  
UNION



[www.umbalk.org](http://www.umbalk.org)

The Official Journal of the Balkan Medical Union  
Founded in 1963 as: *Archives de L'Union Médicale Balkanique*



# BALKAN MEDICAL UNION

---

Founded in 1932 as „L'Union Médicale Balkanique“

## Officers of the Balkan Medical Union

### International Secretary General

Camelia DIACONU, Romania

### Presidents of national sections

|                             |                    |
|-----------------------------|--------------------|
| <b>Albania:</b>             | Ylli POPA          |
| <b>Bulgaria:</b>            | Latchezar TRAYKOV  |
| <b>Cyprus:</b>              | Hasan BESIM        |
| <b>Greece:</b>              | Marianna KARAMANOU |
| <b>North Macedonia:</b>     | Ninoslav IVANOVSKI |
| <b>Republic of Moldova:</b> | Gheorghe CIOBANU   |
| <b>Romania:</b>             | Camelia DIACONU    |
| <b>Turkey:</b>              | Sabri ERGÜNEY      |
| <b>Serbia:</b>              | Vladmila BOJANIC   |

# Archives of the BALKAN MEDICAL UNION



## Founding Editor

[M. POPESCU BUȚEU], Romania

## Editor-in-Chief

Camelia DIACONU, Romania

## Co-Editor-in-Chief

Irinel POPESCU, Romania

## Honorary Editors

Niki AGNANTIS, Greece

George ANDROUTSOS, Greece

Somer ONES, Turkey

Ion ABABII, Republic of Moldova

## Editors

Vladmila BOJANIC, Serbia

Hasan BESIM, Cyprus

Gheorghe CIOBANU,  
Republic of Moldova

Sabri ERGUNEY, Turkey

Ninoslav IVANOVSKI,  
North Macedonia

Marianna KARAMANOU, Greece

Fanny RIBAROVA, Bulgaria

## Assistant Editor

Adriana MILEA, Romania

## Editorial Board

Süha AKPINAR, Cyprus

Raymond ARDAILLOU, France

Kandemir BEROVA, Cyprus

Jean Louis BINET, France

Zoran BOJANIC, Serbia

Andre BOURGEON, France

Giancarlo BRACALE, Italy

Koco CAKALAROSKI, North Macedonia

Emil CEBAN, Republic of Moldova

Olga CERNETCHI, Republic of Moldova

Jean-Michel CORMIER, France

Adrian-Valentin COTIRLET, Romania

Daniel COUTURIER, France

Stella DASKALOPOULOU, Canada

Sergulen DERVISOGLU, Turkey

Roberto di DONATO, Italy

Ertugrul GAZIOGLU, Turkey

Gheorghe GHIDIRIM, Republic of Moldova

Fernando GOMEZ-FERRER BAYO, Spain

Veselina GORANOVA-MARINOVA, Bulgaria

Ioannis GRAMMATIKAKIS, Greece

Mehmet INAN, Cyprus

Ognen IVANOVSKI, North Macedonia

Ioannis KAKADIARIS, USA

Ioannis KARAITIANOS, Greece

Afroditi KARAITIANOU-VELONAKI, Greece

Ashraf W. KHIR, UK

Ioan LASCAR, Romania

Gerald MAURER, Austria

Lucia MAZUR-NICORICI, Republic of Moldova

Minodora MAZUR, Republic of Moldova

Maja MILOJKOVIC, Serbia

Dan MISCHIANU, Romania

Igor NIKOLOV, North Macedonia

Theodore PAPAIOANNOU, Greece

Valentina PETKOVA, Bulgaria

Mentor PETRELA, Albania

Pierre Francois PLOUIN, France

Zivko POPOV, North Macedonia

Theodora PSALTOPOULOU, Greece

Ninel REVENCO, Republic of Moldova

David L. ROWLAND, USA

Boryana RUSEVA, Bulgaria

Zoubeir Ben SAFTA, Tunisie

Adrian SAFTOIU, Denmark, Romania

Vasile SARBU, Romania

Theodoros N. SERGENTANIS, Greece

Galina SEVEROVA, North Macedonia

Andrija ŠMELCEROVIC, Serbia

Nikolaos STERGIOPULOS, Switzerland

Grigore TINICA, Romania

Latchezar TRAYKOV, Bulgaria

Gregory TSOUCALAS, Greece

Ion TINTOIU, Romania

Jovan VASILIEVIC, Serbia

Calin VICOL, Germany

Tsekomir VODENITCHAROV, Bulgaria

Junjie XIAO, China

**Indexed In:** Scopus, SCImago, Chemical Abstracts, EMBASE/Excerpta Medica, Index Copernicus, DOAJ, Scientific World Index, Science Library Index, OAJI, Google Scholar, WorldCat, Harvard Library, Ulrich's Web, HINARI, DRJI, CiteFactor, Gold Rush Open Access Library, SCIPPO, Biblioteca Academiei Române, Eurasian Scientific Journal Index

# CONTENTS

## **EDITORIAL**

- Quality of life – an important endpoint of treatment in patients with heart failure  
*Camelia C. DIACONU* ..... 215

## **ORIGINAL PAPERS**

- Rural-urban disparities of mortality and causes of death in the Republic of Moldova  
*Olga PENINA*.....222
- The risk factors of severe leptospirosis in the transcarpathian region of Ukraine – search for „red flags”  
*Pavlo PETAKH, Vitaliia ISEVYCH, Vasiliy GRIGA, Aleksandr KAMYSHNYI* .....231
- Assessment of clinical symptoms in women with intrahepatic cholestasis of pregnancy  
*Maria CEMORTAN, Irina SAGAIDAC, Olga CERNETCHI, Constantin OSTROFET*..... 238
- Attitudes of students, teachers, and parents regarding COVID-19 screening tests conducted in school  
*Miglena TARNOVSKA, Rositsa DIMOVA, Gergana PETROVA*..... 244
- Fetal anatomical variability of muscles and neurovascular bundles of the anterior brachial region  
*Tatiana V. KHMARA, Oleksandr A. KOVAL, Vitalii V. ILIKA, Mariana I. KRYVCHANSKA*..... 250

## **REVIEWS**

- The drug approaches and the role of healthcare professionals in the management of Alzheimer’s disease  
*Denisa C. MICULAS, Delia M. TIT, Paul A. NEGRU, Alexandra G. TARCE, Alexa F. BUNGAU*..... 260
- Are multiple sclerosis patients protected against some types of cancer?  
*Titus M. VASILE, Razvan I. DUMITRU, Ionut CALOIANU, Aida M. MANOLE, Florentina C. PLESA, Carmen A. SIRBU* ..... 268

## **MINIREVIEW**

- Emergency room: the geriatric patients with severe anaemia – causes and management  
*Bogdan OPRITA, Ruxandra OPRITA, Dragos SCARLAT, Lidia STEFAN* .....277

## **CASE REPORTS**

- The current management of end-stage heart failure: Two case reports  
*Horatiu MOLDOVAN, Oana FRONEA, Claudia NICA, Mihai CACOVEANU, Cristian VOICA, Silvia PREDA, Marian BROASCA, Andra SIBISAN, Robert TIGANASU, Sabina SAFTA, Lucian CALMAC, Ondin ZAHARIA, Liliana MIREA, Camelia C. DIACONU, Horatiu SUCIU* ..... 282

|  |     |
|--|-----|
| <b>Continuous hematospermia for 5 years caused by coitus reservatus as a method of contraception – A case report</b><br><i>Petar A. ANTONOV, Atanas S. IVANOV, Pavel E. STANCHEV, Pencho P. GENOV</i> .....                  | 291 |
| <b>Acute mesenteric thrombosis, small intestine necrosis and peritonitis as a complication of COVID-19 – A case report</b><br><i>Nevena G. IVANOVA</i> .....   | 295 |
| <b>A case of fever and polymorphous rash in a patient with recent Sars-COV-2 infection</b><br><i>Theodoros MICHAILIDIS, Aris LIAKOS, Nikolaos KAKALETSIS, Ioannis AVGERINOS, Stylianos MAMALIS, Sophia ASPRAGATHOU</i> ..... | 301 |
| <b>New-onset isolated acalculia as a consequence of right temporo-parieto-occipital junction infarct</b><br><i>Nataliya NEKRASOVA, Olena TOVAZHNYANSKA, Rhea SINGH, Serhii RUDENKO, Olena RIZNYCHENKO, Kseniia ZUB</i> ..... | 307 |
| <b>Platelet-rich plasma as a novel treatment for lichen sclerosus vulvae: a case report</b><br><i>Nikoleta G. TABAKOVA</i> .....   | 312 |
| <b>Plastic restoration of a facial defect after surgical removal of a large malignant melanoma</b><br><i>Rosen B. TSOLOV</i> .....   | 316 |
| <b>Archives of the Balkan Medical Union</b> .....  | 321 |

# THE RISK FACTORS OF SEVERE LEPTOSPIROSIS IN THE TRANSCARPATHIAN REGION OF UKRAINE – SEARCH FOR „RED FLAGS”

Pavlo PETAKH<sup>1,2✉</sup>, Vitaliia ISEVYCH<sup>3</sup>, Vasiliij GRIGA<sup>2</sup>, Aleksandr KAMYSHNYI<sup>1</sup>

<sup>1</sup> Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine

<sup>2</sup> Department of Biochemistry and Pharmacology, Uzhhorod National University, Uzhhorod, Ukraine

<sup>3</sup> LLC „UZHPHARM”, Uzhhorod, Ukraine

Received August 15<sup>th</sup>, 2022, accepted August 28<sup>th</sup>, 2022

<https://doi.org/10.31688/ABMU.2022.57.3.02>

## ABSTRACT

**Introduction.** Leptospirosis is a re-emerging illness with a wide spectrum of clinical manifestations, from asymptomatic or moderate to severe and lethal results. Leptospirosis can be adequately treated if detected early; however, comparable clinical presentations with various other febrile illnesses or co-infections, as well as laboratory diagnosis problems can result in misdiagnosis, leading to severe illness. Identifying clinical predictors for the severe form of the disease is critical to reduce the disease complications and mortality.

**The objective of the study** was to establish the risk factors for mortality in patients with leptospirosis.

**Materials and methods.** A retrospective study of 102 medical records of patients diagnosed with leptospirosis in the period from 2009 to 2019 was conducted. Quantitative variables in the presence of normal distribution were compared using a paired Student's *t*-test, and in the case of an abnormal distribution, the Mann-Whitney U test was used. The criterion  $\chi^2$  was used for qualitative variables. A two-step cluster analysis was also performed.

## RÉSUMÉ

**Facteurs de risque de leptospirose sévère dans la région transcarpatique de l'Ukraine – recherche «drapeau rouge»**

**Introduction.** La leptospirose est une maladie ré-émergente à spectre large de manifestations cliniques, allant des résultats asymptomatiques ou modérés aux résultats graves et mortels. La leptospirose peut être traitée de manière adéquate si elle est détectée tôt ; cependant, des présentations cliniques comparables avec diverses autres maladies fébriles ou co-infections, ainsi que des problèmes de diagnostic en laboratoire, peuvent conduire à un diagnostic erroné, entraînant une maladie grave. L'identification des prédicteurs cliniques de la forme grave de la maladie est essentielle pour réduire les complications et la létalité de la maladie.

**L'objectif de l'étude** a été d'établir les facteurs de risque de létalité dans la leptospirose.

**Matériaux et méthodes.** Pour déterminer les facteurs de risque de létalité, une étude rétrospective de 102 dossiers médicaux de patients atteints de

✉ Address for correspondence:

Pavlo PETAKH  
Department of Biochemistry and Pharmacology, Uzhhorod National University, Ukraine  
Address: Narodna Square no. 1, Uzhhorod, 88000, Ukraine  
E-mail: pavlo.petakh@uzhnu.edu.ua; Phone: +380991187618

**Results.** The following factors associated with death from leptospirosis have been identified: oliguria (OR, 13.5; 95% confidence interval [CI], 2.56-71.12), serum creatinine and urea levels, direct and total bilirubin, platelets, and white blood cells count.

**Conclusions.** These „red flag” laboratory and clinical characteristics will aid medical personnel in rapidly identifying a patient at risk of death, which is critical in determining the severity of the condition and the need for early intensive care and therapy adjustment.

**Keywords:** leptospirosis, mortality, predictors, risk factors.

#### Abbreviations list

ALT – alanine transaminase  
AST – aspartate aminotransferase  
CFR – case fatality rate  
CI – confidence interval  
CK – creatinine kinase  
DALY – disability-adjusted life year  
MAT – microscopic agglutination test  
OR – odds ratio  
WBC – white blood cells

## INTRODUCTION

Leptospirosis is a major threat to the public health and one of the most important and widely distributed zoonoses in the world<sup>1,2</sup>. Every year, nearly one million people are diagnosed with leptospirosis, with 58,000 of them dying<sup>3</sup>. This disease causes an annual loss of 2.9 million disability-adjusted life years (DALY)<sup>4</sup>.

In the Transcarpathian region of Ukraine, leptospirosis is a significant public health concern. The incidence rate in this region is more than three times higher than the relative incidence in Ukraine and the case fatality ratio (CFR) in leptospirosis in Transcarpathia averages 12.5%, while the national level is 9.8%<sup>5,6</sup>.

The symptom spectrum is extremely broad, and leptospirosis shares clinical signs with many other acute febrile diseases (i.e. flu). Severe manifestations occur in 10–15% of human infections and are typified as Weil’s syndrome (a triad of jaundice, haemorrhage, and acute renal failure), which has a 15–20% case fatality rate and severe pulmonary haemorrhage syndrome (SPHS), which may present as acute respiratory distress and has been linked to case fatality rates more than 50% in several studies<sup>7</sup>.

The early detection of severe or potentially severe cases of leptospirosis may be useful in reducing mortality, which is still quite high in this disease<sup>8,9</sup>. The identification of prognostic factors that lead to

leptospirose dans la période de 2009 à 2019 a été menée. Les variables quantitatives en présence d’une distribution normale ont été comparées à l’aide d’un test t de Student apparié, et dans le cas d’une distribution anormale, le test U de Mann-Whitney a été utilisé. Le critère  $\chi^2$  a été utilisé pour les variables qualitatives. Une analyse par grappes en deux étapes a également été effectuée.

**Résultats.** Les facteurs suivants associés au décès par leptospirose ont été identifiés : oligurie (OR, 13,5 ; intervalle de confiance [IC] à 95 %, 2,56-71,12), taux sériques de créatinine et d’urée, bilirubine directe et totale, plaquettes et numération leucocytaire.

**Conclusions.** Ces caractéristiques cliniques et de laboratoire de type « drapeau rouge » aideront le personnel médical à identifier rapidement un patient à risque de décès, ce qui est essentiel pour déterminer la gravité de l’état et la nécessité de soins intensifs précoces et d’un ajustement thérapeutique.

**Mots-clés:** la leptospirose, mortalité, prédicteurs, facteurs de risque

severe course and death from leptospirosis is important, to establish the need for hospitalization in the intensive care unit and the use of more aggressive therapeutic measures<sup>8,9</sup>.

The presentation of leptospirosis appears to be distinct in different geographical areas around the world<sup>10</sup>. This is especially true because different geographical locations may have different *Leptospira* species and serovars, socioeconomic factors, and environmental factors. Variations in the intrinsic virulence among serovars and species have been proposed to explain some of the differences in disease severity between mild and severe forms of leptospirosis<sup>11</sup>.

The factors that cause severe forms to appear have not been identified<sup>12,13</sup>.

**THE OBJECTIVE OF THE STUDY** was to determine the risk and prognostic factors associated with severe forms of leptospirosis in laboratory-confirmed cases from the Transcarpathian region of Ukraine.

## MATERIALS AND METHODS

### Study design

A retrospective case-control study was conducted in the Transcarpathian Regional Clinical Infectious Diseases Hospital, Uzhhorod, Ukraine. The study protocol included a review of 102 medical records of patients who were hospitalized

**Table 1.** Analysis of demographic and clinical variables.

| Characteristic           | Survivors<br>n = 76<br>(%) | Non-Survivors<br>n = 26<br>(%) | OR (95% CI)            | P-value |
|--------------------------|----------------------------|--------------------------------|------------------------|---------|
| <i>Demographic</i>       |                            |                                |                        |         |
| Age (Years) <sup>a</sup> | 49 (36 - 61)               | 50 (44 - 58)                   | -                      | 0.761   |
| Gender (Male)            | 72 (73.6%)                 | 20 (76.9%)                     | 0.6<br>(0.15 - 2.80)   | 0.730   |
| <i>Symptomatology</i>    |                            |                                |                        |         |
| Fever $\geq 38$ °C       | 64 (84.2%)                 | 32 (61.5%)                     | 0.3<br>(0.07 - 1.23)   | 0.121   |
| Myalgia                  | 58 (76.3%)                 | 20 (76.9%)                     | 1.0<br>(0.23 - 4.59)   | 1.000   |
| Jaundice                 | 62 (81.5%)                 | 26 (100%)                      | 1.4<br>(1.17 - 1.71)   | 0.169   |
| Arthralgia               | 4 (5.2%)                   | 0 (0%)                         | 0.7<br>(0.62 - 0.86)   | 1.000   |
| Oliguria                 | 22 (28.9%)                 | 22 (84.6%)                     | 13.5<br>(2.56 - 71.12) | 0.001   |
| Nausea                   | 18 (23.6%)                 | 10 (38.4%)                     | 2.0<br>(0.52 - 7.72)   | 0.309   |
| Vomiting                 | 20 (26.3%)                 | 8 (30.7%)                      | 1.2<br>(0.31 - 4.95)   | 0.73    |
| Headache                 | 10 (13.1%)                 | 0 (0%)                         | 0.71<br>(0.59 - 0.86)  | 0.311   |
| Abdominal pain           | 4 (5.2%)                   | 4 (15.3%)                      | 3.27<br>(0.41 - 26.01) | 0.266   |

a - IQR (Interquartile Range)

between 2009 and 2019. Leptospirosis was determined according to the criteria of the World Health Organization<sup>14</sup>. Each case was confirmed in the Especially Dangerous Infections (EDIs) of the State Institution Transcarpathian Region, Centre for Disease Control and Prevention of the Ministry of Health of Ukraine, where a microscopic agglutination test (MAT) was conducted. The study did not include individuals who did not have laboratory confirmation of the diagnosis. A standardized questionnaire was used to collect the following information: age, gender, clinical symptoms (fever  $\geq 38$  °, myalgia, jaundice, arthralgia, oliguria, nausea, vomiting, headache, abdominal pain). Urine production of fewer than 400 ml per day was defined as oliguria.

### Statistical analysis

Statistical data were processed using IBM SPSS Statistics 23 software. Quantitative variables in the presence of normal distribution were compared using a paired Student's t-test, and in the case of an abnormal distribution, the Mann-Whitney U test was used. Qualitative variables were compared through the  $\chi^2$  test. Adjusted odds ratios (OR) and 95% confidence intervals (CI) were calculated. The value of p

$<0.05$  was considered significant. A two-step cluster analysis was also performed. The prognostic importance was used and a cut-off level of 0.4 was set.

### RESULTS

Among the 102 leptospirosis patients included in the study, 76 patients (74.5%) survived and 26 (25.5%) died. Demographic data such as age, gender, and clinical signs associated with severe leptospirosis, are shown in Table 1.

Most patients with severe leptospirosis (n = 26, 100%) indicated that they had jaundice, a total of 22 patients had oliguria (84.6%). A total of 20 patients complained of myalgia symptoms (76.9%), and 16 patients had fever (61.5%). A total of 10 patients had nausea (38.4%), while 4 patients with leptospirosis reported abdominal symptoms (15.3%).

The chi-square test showed a significant association between oliguria (p = 0.001) with lethality and severe leptospirosis. Oliguria was the strongest risk factor with an estimated odds ratio of 13.5.

As shown in Table 2, patients who died from leptospirosis had higher serum creatinine levels compared with those who survived, namely  $475.70 \pm 120.95$



**Table 2.** Analysis of laboratory values between survivors and non-survivors among patients with leptospirosis.

| Characteristic                         | Survivors                  | Non-survivors              | P-value |
|--|----------------------------|----------------------------|---------|
|  | n = 76<br>Mean ± SD or (%) | n = 26<br>Mean ± SD or (%) |         |
| ALT (UI/L)                             | 117.55 ± 125.19            | 111.57 ± 87.20             | 0.953   |
| Erythrocyte Sedimentation Rate (mm/hr) | 39.24 ± 17.36              | 45.31 ± 17.40              | 0.163   |
| Creatinine (mmol/L)                    | 190.97 ± 56.26             | 475.70 ± 120.95            | 0.001   |
| Urea (mmol/L)                          | 13.05 ± 9.56               | 30.20 ± 12.33              | 0.001   |
| Total bilirubin (mmol/L)               | 182.50 ± 87.20             | 363.00 ± 110.23            | 0.001   |
| Direct bilirubin (mmol/L)              | 108.85 ± 120.50            | 248.86 ± 95.23             | 0.001   |
| Platelets (10 <sup>9</sup> /L)         | 120.57 ± 121.57            | 45.67 ± 43.57              | 0.005   |
| WBC count (10 <sup>9</sup> /L)         | 14.03 ± 7.47               | 30.8 ± 12.5                | 0.003   |
| Granulocytes (%)                       | 89.90 ± 8.57               | 92.55 ± 7.89               | 0.255   |

**Table 3.** Cluster analysis of lethality predictors in leptospirosis.

| Characteristic                         | Cluster 1 | Cluster 2 | Cluster 3 | Predictor importance |
|--|-----------|-----------|-----------|----------------------|
|  | Mean      | Mean      | Mean      |                      |
| Non-Survivors (%)                      | 0         | 0         | 95.7      | 1.00                 |
| Male                                   | 100       | 0         | 82.6      | 0.88                 |
| Creatinine (mmol/L)                    | 165.91    | 211.85    | 479.63    | 0.51                 |
| Urea (mmol/L)                          | 11.33     | 12.46     | 28.87     | 0.48                 |
| Direct bilirubin (mmol/L)              | 120.21    | 71.01     | 242.23    | 0.29                 |
| Total bilirubin (mmol/L)               | 191.90    | 130.86    | 345.66    | 0.22                 |
| Platelets (10 <sup>9</sup> /L)         | 125.72    | 101.50    | 46.83     | 0.10                 |
| Age (y)                                | 44.88     | 52.12     | 52.83     | 0.08                 |
| Granulocytes (%)                       | 86.95     | 89.51     | 90.94     | 0.05                 |
| Erythrocyte Sedimentation Rate (mm/hr) | 40.90     | 36.92     | 43.87     | 0.02                 |
| ALT (IU/L)                             | 120.86    | 112.92    | 112.7     | 0.02                 |

mmol/L versus 190.97±56.26 mmol/L, respectively (p = 0.001). Statistically significant changes were also found in the levels of laboratory parameters such as urea (p = 0.001), total bilirubin (p = 0.001), direct bilirubin (p = 0.001) platelet level (p = 0.005) and white blood cells (WBC) count (p = 0.003). Alanine aminotransferase (ALT), erythrocyte sedimentation rate, and granulocyte percentage in the blood were not associated with leptospirosis lethality (p > 0.05).


A cluster analysis of probable predictors was also performed. Three clusters were formed, the size of each cluster is shown in Figure 1.

The first and second clusters were formed from surviving patients (the first cluster was formed only from male patients and the second only from female patients). The third cluster consisted of most patients who did not survive. As can be seen from Table 3, the most important factors associated with leptospirosis lethality are gender (male), serum creatinine, and urea.

## DISCUSSION

This study was carried out to determine the predictive factors for lethality and severe leptospirosis in the Transcarpathian region. The findings suggest that oliguria is a risk factor for severe leptospirosis. This sign can be recognized after hospitalization, and early identification and control of diuresis can alert the treating physician to the possibility that the patient will develop severe leptospirosis. As a result, aggressive treatment should start immediately.

The kidney is one of the main targets of *Leptospira*, with kidney damage occurring in 20–85% of patients<sup>15</sup>. Renal failure, especially in oliguric forms of leptospirosis, is a well-established predictor of death and it is also associated with more frequent pulmonary involvement<sup>16,17</sup>. Histologically, there are spirochetes in the renal tubules, interstitial nephritis, and glomerular damage with tubular necrosis<sup>18</sup>. The cause is unknown, but is thought to be a mix of



**Figure 1.** Cluster sizes of patients with leptospirosis. The first (51.5%) and second (24.7%) clusters were formed from surviving patients (the first cluster was formed only from male patients and the second only from female patients). The third (23.7%) cluster consisted of most patients who did not survive.

direct toxic injury, immune-mediated responses, and circulatory collapse<sup>19</sup>.

The results of our study suggest that risk stratification for patients with leptospirosis should not be relied on the presence of icterus. Jaundice occurs because of damage to the vessels of the hepatic capillaries without hepatocellular necrosis. There are retrospective studies that confirm<sup>20,21</sup>, or deny<sup>9,10</sup> the role of jaundice as a predictor of death in this infectious disease.

Myalgia is a symptom of leptospirosis and is often described as affecting the back and legs<sup>22</sup>. In most studies, myalgia was not a factor associated with lethality in leptospirosis<sup>9,23</sup>. Histologically, there is focal necrosis of muscle fibres, with a slight increase in creatinine kinase (CK) as a result<sup>24</sup>. A study by Dupont et al. in France found that CK levels were higher in non-survived patients with leptospirosis<sup>8</sup>.

Headache is a common symptom of leptospirosis, and it is frequently described as severe and connected with vomiting. Patients may have impaired consciousness in the early stages, followed by meningitis symptoms in one-quarter of cases during the immunological phase<sup>17</sup>. In our study the headache wasn't a common presentation.

In our study, patients who died had higher total and direct bilirubin levels than those who recovered. Several scientific articles have proven the importance of hyperbilirubinemia as a predictor of lethality and severe leptospirosis<sup>8,10</sup>. In leptospirosis, liver enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are moderately increased, suggesting that liver impairment is generally mild and resolves with time<sup>17</sup>. The role of liver aminotransferases as a factor of disease severity or lethality needs to be further researched, as there is evidence that confirms<sup>25</sup>

or refutes<sup>9,26</sup> the role of these biochemical parameters in patients with leptospirosis. An AST/ALT ratio > 3 may indicate a poorer prognosis<sup>27</sup>.

Thrombocytopenia, which is frequent in leptospirosis, is another key risk factor for a severe course of the disease and lethality<sup>28</sup>. Thrombocytopenia in leptospirosis may be caused by specific *Leptospira* strains that directly activate platelets, according to one theory<sup>29</sup>. Thrombocytopenia in the acute phase of the disease may play a role in haemorrhagic disorders. In many studies, thrombocytopenia has been identified as one of the most common causes of severe course and death<sup>8,10,30,31</sup>. Uraemia may also be a factor in the acute phase of the disease that causes bleeding. The pathophysiology of bleeding in uraemia is complex, nevertheless alterations in platelet-platelet and platelet-vessel wall interaction play a crucial role. Uremic toxins present in the bloodstream contribute to platelet dysfunction<sup>32</sup>.

Increased levels of creatinine and urine in the blood indicate kidney damage and the possibility of acute kidney failure, one of the most common and decisive predictors of death in leptospirosis<sup>30</sup>. Jaundice (Weil's syndrome) is the clinical syndrome most closely associated with the risk of death, so the presence of renal failure in leptospirosis patients should receive special attention<sup>31</sup>.

The age, which did not differ between the two groups in our study ( $p > 0.05$ ), but did in certain studies<sup>8,10</sup>, is one of the demographic variables that can be discussed; however, patients who died from leptospirosis were older than those who recovered. Most studies<sup>8,10</sup>, including our, have found that although gender is not a significant factor in leptospirosis lethality, men have a higher incidence of the disease than women.

## CONCLUSIONS

In our study, oliguria, serum creatinine and urea levels, as well as levels of direct and total bilirubin, platelets, and WBC count were found as important predictors of lethality in leptospirosis. These „red flag” laboratory and clinical characteristics will aid medical personnel in rapidly identifying a patient at risk of death, which is critical in determining the severity of the condition and the need for early intensive care and therapy adjustment.

## Author Contributions:

Conceptualization, P.P., and G.V.; methodology, I.V, and G.V.; software, P.P.; validation P.P.; formal analysis, I.V, and G.V.; investigation, P.P., I.V, and G.V.; resources, P.P.; data curation, P.P.; writing—original draft preparation, P.P., I.V, and G.V.; writing—review and editing, I.V and G.V.; visualization, P.P.; supervision, P.P.; project administration, P.P.. All authors have read and agreed with the final version of this article.

## Compliance with Ethics Requirements:

„The authors declare no conflict of interest regarding this article”

„The authors declare that all the procedures and experiments of this study respect the ethical standards in the Helsinki Declaration of 1975, as revised in 2008(5), as well as the national law. Informed consent was obtained from all the patients included in the study „

„No funding for this study”

## Acknowledgments

None

## REFERENCES

- Adler B, de la Peña Moctezuma A. Leptospira and leptospirosis. *Veterinary Microbiology*. 2010;140(3-4):287-296.
- Ullmann L, Langoni H. Interactions between environment, wild animals and human leptospirosis. *Journal of Venomous Animals and Toxins including Tropical Diseases*. 2011;17:119-129.
- Costa F, Hagan JE, Calcagno J, et al. Global morbidity and mortality of leptospirosis: a systematic review. *PLoS Neglected Tropical Diseases*. 2015;9(9):e0003898.
- Torgerson PR, Hagan JE, Costa F, et al. Global burden of leptospirosis: estimated in terms of disability adjusted life years. *PLoS Neglected Tropical Diseases*. 2015;9(10):e0004122.
- Markovych O, Tymchuk V, Kolesnikova I. Leptospirosis in Zakarpattia Oblast (2005–2015). *Vector-Borne and Zoonotic Diseases*. 2019;19(5):333-340.
- Hopko N. Epidemiolohichni osoblyvosti leptospirozu v Ukraini v umovakh sohodennia. *Visnyk Problem Biologii i Medytsyny*. 2017(4 (3)):84-86.
- Gouveia EL, Metcalfe J, De Carvalho ALF, et al. Leptospirosis-associated severe pulmonary hemorrhagic

syndrome, Salvador, Brazil. *J Emerging Infectious Diseases*. 2008;14(3):505.

- Dupont H, Dupont-Perdrizet D, Perie JL, Zehner-Hansen S, Jarrige B, Daijardin JB. Leptospirosis: prognostic factors associated with mortality. *Clinical Infectious Diseases*. 1997;25(3):720-724.
- Daher EDF, Soares DS, de Menezes Fernandes ATB, et al. Risk factors for intensive care unit admission in patients with severe leptospirosis: a comparative study according to patients' severity. *BMC Infectious Diseases*. 2015;16(1):1-7.
- Spichler AS, Vilaça PJ, Athanazio DA, et al. Predictors of lethality in severe leptospirosis in urban Brazil. *The American Journal of Tropical Medicine and Hygiene*. 2008;79(6):911.
- Philip N, Lung Than LT, Shah AM, Yuhana MY, Sekawi Z, Neela VK. Predictors of severe leptospirosis: a multicentre observational study from Central Malaysia. *J BMC Infectious Diseases*. 2021;21(1):1-6.
- Herrmann-Storck C, Saint Louis M, Foucand T, et al. Severe leptospirosis in hospitalized patients, Guadeloupe. *J Emerging Infectious Diseases*. 2010;16(2):331.
- Paganin F, Bourdin A, Dalban C, et al. Leptospirosis in Reunion Island (Indian Ocean): analysis of factors associated with severity in 147 confirmed cases. *J Intensive Care Medicine*. 2007;33(11):1959-1966.
- Organization WH. *Human leptospirosis: guidance for diagnosis, surveillance and control*. World Health Organization; 2003.
- Meneses GC, Silva Junior GBd, Tôrres PPBF, et al. Novel kidney injury biomarkers in tropical infections: a review of the literature. *Rev Inst Med Trop Sao Paulo*. 2020;62:e14.
- Silva Junior GB, Abreu KLS, Mota RM, et al. RIFLE and Acute Kidney Injury Network classifications predict mortality in leptospirosis-associated acute kidney injury. *J Nephrology*. 2011;16(3):269-276.
- Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. *J Lancet Infect Dis*. 2003;3:757-771.
- Sellors P, Watson RF, Bate R, Bentham GL, Haigh K. Clinical Features and Severity of Leptospirosis Cases Reported in the Hawke's Bay Region of New Zealand. *Journal of Tropical Medicine*. 2021;2021:5567081.
- Cerqueira TB, Athanazio DA, Spichler AS, Seguro AC. Renal involvement in leptospirosis: new insights into pathophysiology and treatment. *Brazilian Journal of Infectious Diseases*. 2008;12(3):248-252.
- Durmaz Cetin B, Harmankaya O, Hasman H, Gunduz A, Oktar M, Seber E. Acute renal failure: a common manifestation of leptospirosis. *Renal Failure*. 2004;26(6):655-661.
- Daher EF, Silva Jr GB, Karbage NN, et al. Predictors of oliguric acute kidney injury in leptospirosis. *Nephron Clinical Practice*. 2009;112(1):c25-c30.
- Vijayachari P, Sugunan A, Shriram A. Leptospirosis: an emerging global public health problem. *Journal of Biosciences*. 2008;33(4):557-569.
- Al-shere TA, Ujiie M, Suzuki M, et al. Outbreak of leptospirosis after flood, the Philippines. *Emerg Infect Dis*. 2009. 2012;18(1):91.
- Lim V. Leptospirosis: a re-emerging infection. *The Malaysian Journal of Pathology*. 2011;33(1):1.
- Sandhu RS, Ismail HB, Ja'afar MHB, Rampal S. The predictive factors for severe leptospirosis cases in kedah. *J Tropical Medicine Infectious Disease*. 2020;5(2):79.
- Hochedez P, Theodose R, Olive C, et al. Factors associated with severe leptospirosis, Martinique, 2010–2013. *Emerging infectious diseases*. 2015;21(12):2221.

27. Chang ML, Yang CW, Chen JC, et al. Disproportional exaggerated aspartate transaminase is a useful prognostic parameter in late leptospirosis. *World Journal of Gastroenterology*. 2005;11(35):5553-5556.
28. Daher EF, Silva GB, Silveira CO, et al. Factors associated with thrombocytopenia in severe leptospirosis (Weil's disease). *Clinics*. 2014;69:106-110.
29. Wagenaar JF, Goris MG, Sakundarno M, et al. What role do coagulation disorders play in the pathogenesis of leptospirosis? *Tropical Medicine & International Health*. 2007;12(1):111-122.
30. Panaphut T, Domrongkitchaiporn S, Thinkamrop B. Prognostic factors of death in leptospirosis: a prospective cohort study in Khon Kaen, Thailand. *International Journal of Infectious Diseases*. 2002;6(1):52-59.
31. Tantitanawat S, Tanjatham S. Prognostic factors associated with severe leptospirosis. *Journal-Medical Association of Thailand*. 2003;86(10):925-931.
32. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. *Seminars in Thrombosis and Hemostasis* 2004;30(5):579-89.